Chandran Vinod, Scher Jose U
Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada,
Curr Rheumatol Rep. 2014 Nov;16(11):453. doi: 10.1007/s11926-014-0453-4.
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. About a quarter of patients with psoriasis of the skin will develop PsA, although it is currently challenging-if not impossible-to determine a priori which individuals will progress. Identification of biomarkers for screening, disease activity, joint damage, treatment response and comorbidities are therefore perceived as important clinical needs in the field. Over the last few years, several lines of investigation have advanced our knowledge of new markers for PsA and its outcomes, including genomic, proteomic, cellular and tissue studies. Imaging studies utilizing ultrasonography have been applied to better understand the natural history of the disease. Novel biomarkers, such as soluble proteins and microbiomics, are also being described. Although no biomarker has yet been validated for use in clinical practice, discovery studies are in progress and validation cohorts are being designed. In this report, we review the latest progress in biomarker research in PsA and its potential implications in pathogenesis, diagnosis and therapy.
银屑病关节炎（PsA）是一种与银屑病相关的炎性关节炎。约四分之一的皮肤银屑病患者会发展为PsA，尽管目前要事先确定哪些个体将会病情进展即便并非不可能也是具有挑战性的。因此，识别用于筛查、疾病活动度、关节损伤、治疗反应及合并症的生物标志物被视为该领域重要的临床需求。在过去几年中，多条研究路线增进了我们对PsA及其转归新标志物的认识，包括基因组学、蛋白质组学、细胞和组织研究。利用超声的影像学研究已被用于更好地理解该疾病的自然病程。新型生物标志物，如可溶性蛋白和微生物组学，也正在被描述。尽管尚无生物标志物被证实可用于临床实践，但探索性研究正在进行中，验证队列也正在设计。在本报告中，我们综述了PsA生物标志物研究的最新进展及其在发病机制、诊断和治疗中的潜在意义。
